Stephen J. Schuster, MD, Director of the Lymphoma Program & Lymphoma Translational Research at the Abramson Cancer Center of the University of Pennsylvania, infuses this presentation with more than thirty years of insight from practice to offer a frank consideration of the clinical trials presented at ASH 2015 for the treatment of the non-Hodgkin, diffuse large B cell, mantle cell and follicular lymphomas. Highlights include optimistic outcomes from the Penn CTL019 T cell therapy study for relapsed/refractory CD19+ NHL, which included patients with NHL, follicular and mantle cell lymphomas.
Related Links
Published
December 7, 2016
Created by
BROADCASTMED